Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Rosty Raykov Sells 10,000 Shares of Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Rosty Raykov sold 10,000 shares of the firm’s stock in a transaction on Friday, April 4th. The shares were sold at an average price of $5.25, for a total transaction of $52,500.00. Following the transaction, the director now directly owns 61,156 shares of the company’s stock, valued at $321,069. The trade was a 14.05 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Rosty Raykov also recently made the following trade(s):

• On Wednesday, March 5th, Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $6.79, for a total value of $67,900.00.
• On Wednesday, February 5th, Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $6.66, for a total value of $66,600.00.
• On Monday, January 6th, Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $6.08, for a total value of $60,800.00.

Fennec Pharmaceuticals Trading Down 6.1 %

Shares of Fennec Pharmaceuticals stock opened at $5.25 on Friday. The business has a 50-day moving average price of $6.51 and a two-hundred day moving average price of $5.72. Fennec Pharmaceuticals Inc has a 1-year low of $3.96 and a 1-year high of $11.11. The company has a market cap of $144.84 million, a P/E ratio of -52.49 and a beta of 0.32.

Institutional Investors Weigh In On Fennec Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Solas Capital Management LLC lifted its stake in Fennec Pharmaceuticals by 17.0% in the fourth quarter. Solas Capital Management LLC now owns 2,250,919 shares of the company’s stock valued at $14,226,000 after buying an additional 327,383 shares during the period. Rosalind Advisors Inc. acquired a new position in shares of Fennec Pharmaceuticals during the fourth quarter valued at about $7,962,000. State Street Corp boosted its position in shares of Fennec Pharmaceuticals by 2.2% during the 3rd quarter. State Street Corp now owns 328,259 shares of the company’s stock worth $1,641,000 after purchasing an additional 7,053 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Fennec Pharmaceuticals by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 303,090 shares of the company’s stock valued at $1,916,000 after buying an additional 3,792 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in Fennec Pharmaceuticals by 10.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 61,146 shares of the company’s stock valued at $386,000 after buying an additional 5,694 shares in the last quarter. Institutional investors and hedge funds own 55.51% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on FENC. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Fennec Pharmaceuticals in a research note on Tuesday, March 11th. Wedbush restated an “outperform” rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a research report on Monday, March 10th.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.